Previous studies have indicated that patients with triple-negative breast cancer have worse clinical outcomes compared with hormone-receptor-positive (ER+ and PR+) and ERBB2-positive (ERBB2+) breast cancer patients [6,7,8]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.